TY - JOUR
T1 - An Artificial Intelligence-Digital Pathology Algorithm Predicts Survival After Radical Prostatectomy From the Prostate, Lung, Colorectal, and Ovarian Cancer Trial
AU - Li, Eric V.
AU - Ren, Yi
AU - Griffin, Jacqueline
AU - Han, Colin
AU - Yamashita, Rikiya
AU - Mitani, Akinori
AU - Zhou, Ruoji
AU - Huang, Huei Chung
AU - Yang, Ximing
AU - Feng, Felix Y.
AU - Esteva, Andre
AU - Patel, Hiten D.
AU - Schaeffer, Edward M.
AU - Cooper, Lee A.D.
AU - Ross, Ashley E.
N1 - Publisher Copyright:
© 2025 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH, INC.
PY - 2025
Y1 - 2025
N2 - Purpose:Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer-specific mortality (PCSM) and overall survival (OS) among patients undergoing RP with digitized RP specimens.Materials and Methods:The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993 to 2001 to cancer screening or control. A subset of patients who underwent RP with available digitized histopathological images and subsequent survival data were identified. Distant metastasis (DM) and PCSM MMAIs originally trained on biopsy slides for patients undergoing radiation were evaluated for prediction of PCSM and OS. Cox proportional hazards modeling and Kaplan-Meier survival curve analysis were used.Results:In total, 1032 patients who underwent RP with median follow-up of 17 years (IQR, 14.3, 19.3 years) were identified. MMAI algorithms for PCSM and DM both predicted PCSM (HR, 2.31, 95% CI, 1.6-3.35, P <.001 and HR, 1.96, 95% CI, 1.35-2.85, P <.001, respectively). Similarly, DM and PCSM MMAI predicted OS (HR, 1.22, 95% CI, 1.01-1.47, P =.04 and HR, 1.19, 95% CI, 1.02-1.4, P =.03).Conclusions:Locked MMAI algorithms previously developed and validated on biopsy specimens from patients undergoing radiation for prostate cancer successfully predicted clinical outcomes when applied to RP specimens from patients treated with surgery. MMAI models and other biomarkers may help select patients who may benefit from postoperative treatment intensification with androgen deprivation therapy or radiation.
AB - Purpose:Clinical variables alone have limited ability to determine which patients will have recurrence after radical prostatectomy (RP). We evaluated the ability of locked multimodal artificial intelligence (MMAI) algorithms trained on prostate biopsy specimens to predict prostate cancer-specific mortality (PCSM) and overall survival (OS) among patients undergoing RP with digitized RP specimens.Materials and Methods:The Prostate, Lung, Colorectal, and Ovarian Cancer Screening Randomized Controlled Trial randomized subjects from 1993 to 2001 to cancer screening or control. A subset of patients who underwent RP with available digitized histopathological images and subsequent survival data were identified. Distant metastasis (DM) and PCSM MMAIs originally trained on biopsy slides for patients undergoing radiation were evaluated for prediction of PCSM and OS. Cox proportional hazards modeling and Kaplan-Meier survival curve analysis were used.Results:In total, 1032 patients who underwent RP with median follow-up of 17 years (IQR, 14.3, 19.3 years) were identified. MMAI algorithms for PCSM and DM both predicted PCSM (HR, 2.31, 95% CI, 1.6-3.35, P <.001 and HR, 1.96, 95% CI, 1.35-2.85, P <.001, respectively). Similarly, DM and PCSM MMAI predicted OS (HR, 1.22, 95% CI, 1.01-1.47, P =.04 and HR, 1.19, 95% CI, 1.02-1.4, P =.03).Conclusions:Locked MMAI algorithms previously developed and validated on biopsy specimens from patients undergoing radiation for prostate cancer successfully predicted clinical outcomes when applied to RP specimens from patients treated with surgery. MMAI models and other biomarkers may help select patients who may benefit from postoperative treatment intensification with androgen deprivation therapy or radiation.
KW - artificial intelligence
KW - prognosis
KW - prostatic neoplasms
UR - http://www.scopus.com/inward/record.url?scp=85217903333&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85217903333&partnerID=8YFLogxK
U2 - 10.1097/JU.0000000000004435
DO - 10.1097/JU.0000000000004435
M3 - Article
C2 - 39841869
AN - SCOPUS:85217903333
SN - 0022-5347
JO - Journal of Urology
JF - Journal of Urology
M1 - 04435
ER -